Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival
I Norheim, K Oberg, E Theodorsson-Norheim, P G Lindgren, G Lundqvist, A Magnusson, L Wide, E Wilander, I Norheim, K Oberg, E Theodorsson-Norheim, P G Lindgren, G Lundqvist, A Magnusson, L Wide, E Wilander
Abstract
In a prospective study of 103 patients with carcinoid tumors consecutively referred for medical treatment, the most common sites of the primary tumors were the ileum (73%), bronchi (7%), and jejunum (4%). All patients had local metastases, and 96 (93%) also had liver metastases. The most common initial symptoms were diarrhea (32%), ileus (25%), and flush (23%). The overall frequency of diarrhea was 84% and of flush was 75%. Heart insufficiency caused by cardiac valve disease was seen in 33% of the patients. The carcinoid syndrome, including flush, diarrhea, and elevated urinary 5-hydroxyindole acetic acid (5-HIAA) concentrations, was manifested by 69 patients (67%), 64 of whom (93%) had carcinoid tumors of mid-gut origin. Elevated urinary 5-HIAA was found in 91 patients (88%), of which 89 displayed liver metastases. The plasma concentration of the tachykinin neuropeptide K (NPK) was elevated in 67 patients (66%), 63 of whom had tumors of the mid-gut region. Serum pancreatic polypeptide (PP) and human chorionic gonadotrophin alpha levels were elevated in 43% and 28% of the patients, respectively, and the highest levels were found in patients with metastatic bronchial carcinoid tumors. Thirty-nine of the 103 patients are now dead; 18 died of tumor progression, whereas 14 patients died of heart failure secondary to a carcinoid tricuspidal valve insufficiency. The estimated median survival from the time of histologic diagnosis was 14 years, and from the time of carcinoid syndrome was 8 years.
References
- J Pathol. 1986 Feb;148(2):141-7
- Acta Med Scand. 1956 Dec 8;156(2):73-83
- J Clin Invest. 1966 Feb;45(2):173-8
- Acta Med Scand. 1974 Sep;196(3):177-80
- Anat Anz. 1964 Jul 31;115:81-2
- Clin Chim Acta. 1977 Sep 1;79(2):357-62
- Lancet. 1968 Nov 16;2(7577):1053-4
- Nature. 1985 May 2-8;315(6014):61-3
- Ann Surg. 1982 Jul;196(1):33-7
- Arch Surg. 1984 Apr;119(4):375-8
- Regul Pept. 1984 Nov;9(4):245-57
- Acta Radiol Diagn (Stockh). 1982;23(6):653-6
- Acta Pathol Microbiol Scand A. 1976 Jul;84(4):322-30
- Surg Gynecol Obstet. 1973 Oct;137(4):637-44
- Am J Cardiol. 1968 Mar;21(3):376-87
- Acta Soc Med Ups. 1968;73(5-6):243-70
- J Clin Endocrinol Metab. 1974 Feb;38(2):329-33
- Clin Chim Acta. 1981 Feb 19;110(1):71-6
- N Engl J Med. 1983 Jul 21;309(3):129-33
- Biochem Biophys Res Commun. 1985 Aug 30;131(1):77-83
- Acta Endocrinol (Copenh). 1981 Oct;98(2):256-60
- Acta Neuropathol. 1985;66(4):306-10
- Arch Surg. 1982 May;117(5):732-7
- Ann Surg. 1985 Jan;201(1):81-6
- Scand J Gastroenterol. 1977;12(8):923-7
- J Neuropathol Exp Neurol. 1965 Jan;24:130-5
- Am J Med. 1984 Apr;76(4):605-16
- Cancer. 1980 Jan 1;45(1):104-7
- Acta Chir Scand. 1983;149(6):607-16
- J Clin Endocrinol Metab. 1967 Sep;27(9):1285-9
- Cancer. 1983 Mar 1;51(5):878-81
- Lancet. 1963 Feb 2;1(7275):238-9
- J Histochem Cytochem. 1981 Dec;29(12):1425-30
- J Clin Endocrinol Metab. 1986 Sep;63(3):605-12
- Acta Endocrinol (Copenh). 1985 May;109(1):13-8
- Acta Med Scand. 1981;210(3):145-52
Source: PubMed